Oliceridine pain pumps boosted early recovery after gynecologic tumour surgery in a trial
A randomized trial of 94 women found that oliceridine-based patient-controlled analgesia produced higher day-one recovery scores than sufentanil after laparoscopic gynecological...
원문 링크: WordPress 원문
SHAWN BIO · EVIDENCE BRIEF
An anesthesiology team at Guangxi Medical University Cancer Hospital reported in Annals of Medicine on 12 August 2026 that among 94 women recovering from laparoscopic gynecological tumour surgery , oliceridine-controlled pain pumps produced higher day-one Quality of Recovery-40 scores than sufentanil pumps . Because the trial followed only these 94 women for three postoperative days and its full text is paywalled, replication in larger cohorts is still needed , yet the result gives the first patient-centred head-to-head comparison of two self-controlled opioid pumps after gynecologic cancer surgery .
The randomized trial was published online in Annals of Medicine on 12 August 2026 , putting the first peer-reviewed comparison of oliceridine- versus sufentanil-based patient-controlled analgesia after gynecological tumour surgery into the public record.
QoR-40 on postoperative day 1
182.9 vs 177.5 QoR-40 points
Oliceridine versus sufentanil group means.
Trial population
94 women
Randomized into two parallel analgesia groups.
Safety observation window
3 post-op days
Adverse events and recovery scores followed after surgery.
AI-generated conceptual illustration; not study data.
Day-one recovery scores favoured the oliceridine pump
Participants received one of two patient-controlled intravenous analgesia regimens after laparoscopic gynecological tumour surgery: oliceridine 1.5 mg loading dose plus a 0.55 mg/kg self-controlled infusion, or the established sufentanil regimen of 10 μg plus 3 μg/kg. The headline figure belongs to the whole randomized comparison: the 94 women who underwent elective laparoscopic gynecological tumour resection and were allocated to oliceridine-based versus sufentanil-based patient-controlled analgesia, and it expresses their average Quality of Recovery-40 state on postoperative day 1 against that same two-arm denominator, so the gap reflects what was measured across both study groups rather than a selected subgroup. Patient-controlled analgesia means the patient presses a button to self-deliver small, pre-set opioid doses through an infusion pump within safety limits set by clinicians, so the design compares two drugs delivered through the same self-administered route rather than two different care routines.
Study design: Two-arm randomized clinical trial of oliceridine versus sufentanil patient-controlled intravenous analgesia.
Enrolled population: 94 female patients, elective laparoscopic gynecological tumour resection.
Analysis population: Abstract gives no separate analysis counts; enrolled group reported as-is.
Primary endpoint: Quality of Recovery-40 score on postoperative day 1.
The QoR-40 is a validated questionnaire in which patients rate comfort, emotions and physical function after surgery, with higher scores indicating a better recovery. On that first day the oliceridine group averaged 182.9 vs 177.5 QoR-40 points with sufentanil (standard deviations 3.1 and 3.9 respectively) — a difference the authors reported as statistically significant (p below 0.001 per the abstract, sourced from the PubMed record) — and the advantage held across the first three postoperative days. Pain control looked comparable, with no significant differences in numeric rating scale pain scores or HADS-A anxiety scores. The groups did separate on a frailty measure: the median FRAIL score was lower with oliceridine on postoperative day 2 (p = 0.018), and the authors concluded that oliceridine lowered incidences of postoperative frailty, nausea and vomiting. Both pumps therefore delivered similar relief, but the oliceridine group reported feeling better recovered with a lighter side-effect burden.
Early recovery is the outcome patients feel first
For women having gynecological cancer surgery, the days immediately after the operation shape whether they can sit up, eat, sleep and go home on schedule — and nausea, sedation and opioid side effects are often what delay those steps. The point of interest here is that oliceridine matched sufentanil on pain scores yet accompanied higher overall recovery scores, which suggests the benefit comes through tolerability rather than stronger analgesia. Oliceridine is described in the abstract as a biased μ-opioid receptor agonist, a design intended to preserve pain relief while trimming classical opioid adverse effects; seeing the advantage show up in frailty and nausea-related endpoints rather than in pain or anxiety scores fits that hypothesis in a tentative, direction-of-effect way. For anesthesia teams planning postoperative regimens after laparoscopic gynecological procedures, that raises the practical prospect that drug choice within the same pump format can shift early recovery without sacrificing analgesia. The caveat is equally important: this is one single-centre trial of fewer than one hundred women, so the finding should currently read as a promising signal that needs confirmation, not as grounds to change protocols.
AI-generated conceptual illustration; not study data.
A small single-centre window on three days of recovery
Several boundaries temper the result. The enrolled group comprised 94 women at one Chinese cancer hospital undergoing one operation type, so generalization to men, other surgeries or other settings is unproven. Follow-up covered only 3 post-op days, leaving longer-term recovery, persistent pain and opioid-related complications unmeasured. The reported safety window therefore captures early events such as nausea, vomiting and frailty within those three days, and does not extend to late adverse effects, dependence, readmission or oncologic outcomes. The abstract does not state how many participants were included in each arm’s analysis, and the full text is paywalled — the publisher page returned an access error and no open full text is indexed — so per-group denominators and the complete adverse-event table cannot yet be independently checked. This is also an academic trial result, not a regulatory review: nothing here changes the authorization status of oliceridine, and a better recovery score is not evidence of superior long-term safety. Registration is listed as ChiCTR2400094271 in the Chinese Clinical Trial Registry, and readers should wait for the full trial report before treating these numbers as definitive.
Confirmation in larger cohorts comes next
AI-generated conceptual illustration; not study data.
The immediate next step is replication: larger, preferably multi-centre randomized trials that re-test oliceridine-based patient-controlled analgesia in broader surgical populations, report per-group analyses transparently, and follow patients well beyond the three-day window. Comparisons against other modern opioids and within enhanced-recovery pathways would clarify whether the recovery advantage is drug-specific or regimen-specific. Until such data are public, the reasonable reading is that oliceridine offers analgesia comparable to sufentanil with a possibly smoother early recovery profile after laparoscopic gynecological tumour surgery — encouraging, but single-trial evidence. Patients facing this surgery can take one grounded point into their consultation: different self-controlled pain pumps may deliver similar pain relief with different recovery experiences, and the choice belongs in a conversation with the anesthesia team, not in a headline.
Evidence boundary. This article summarizes one randomized clinical trial of 94 women at a single centre with outcomes through postoperative day 3. It does not establish long-term safety, does not apply to other surgeries or populations, and does not reflect any regulatory approval decision. Registration is not a result; a single trial is not a standard of care.
References. PubMed record: Oliceridine used for patient-controlled analgesia on postoperative quality of recovery in patients undergoing laparoscopic gynecological tumour resection (Annals of Medicine, 2026); trial registration ChiCTR2400094271 (Chinese Clinical Trial Registry) as listed in the record; publisher DOI page: 10.1080/07853890.2026.2714613.
This article is a news summary of a published trial and is not medical advice. Treatment decisions, including choice of postoperative analgesia, belong with your own clinical team.
다음 액션
실전 운영/리서치 사례를 주간으로 받아보려면 블로그를 북마크하고, 필요한 주제는 문의로 남겨주세요.
